Article
RAS mutations that have a major impact on current cancer genomic medicine
2022-09-16
Abstract excerpt
The status of rat sarcoma viral oncogene homolog (RAS) proteins is a negative predictive biomarker for anti-epidermal growth factor receptor (EGFR) therapy in metastatic colon cancer. In the phase 2 CHRONOS trial, patients with mutant gene(s) are ineligible for anti-EGFR therapy. However, our studies revealed that splicing caused by the RAS mutations, which were considered oncogenic, generates unfunctional RAS fam...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 5c91fbc8-ee2d-5ed9-b09d-cffdab07c635
- DOI
- 10.32388/jwnw97
